In response to a significant decrease in early-stage research spending, Evotec, a leading German company focusing on drug discovery and contract development and manufacturing (CDMO), is undertaking substantial strategic changes. Under the new leadership of CEO Christian Wojczewski, Evotec has
The biopharmaceutical industry stands at the forefront of medical innovation, driving advances that significantly impact healthcare and treatment options worldwide. This sector involves developing and producing drugs derived from biological sources and is continually evolving with breakthroughs
In an ambitious move to optimize essential quality management and operational processes, Quest Nutra Pharma has partnered with Kissflow to harness the power of its Low-Code platform. This collaboration marks a significant step toward increased efficiency and accuracy in the field of nutraceutical
The pharmaceutical industry is undergoing a significant transformation driven by the advent of pharma analytics. Utilizing modern data analytics tools has revolutionized various stages of drug development, manufacturing, and distribution. This article explores how these advancements are shaping the
In a significant leap for diagnostic science, researchers from Tohoku University have unveiled a new approach leveraging composite polymer particles adorned with gold nanoparticles (GNDPs) to enhance the accuracy and sensitivity of tests for infectious diseases such as the influenza virus and
The biopharmaceutical industry is undergoing a transformative shift towards sustainability, driven by the dual imperatives of environmental responsibility and regulatory compliance. In a significant move to support this transition, Thermo Fisher Scientific has unveiled novel biobased versions of
TPG's recent infusion of $580 million into their Life Science Innovations fund is a remarkable move, aimed at supporting advancements in breakthrough technologies and achieving clinical proof-of-concept for emerging life science companies. The substantial financial backing will target a broad
Aeterna Zentaris Inc. has undergone a major transformation, rebranding itself as COSCIENS Biopharma Inc. This corporate transition reflects not only a nominal change but also a strategic overhaul aimed at better representing the company's diversified portfolio and innovative drive within the
The recent collaboration between biotech creation engines Two River and Third Rock Ventures has led to the formation of TRC 2004, which has licensed a bispecific T-cell engager (BiTE) from Genor Biopharma. TRC 2004 has acquired the ex-China rights to the CD20/CD3-targeting BiTE, known as GB261,
Freudenberg Medical, known for its contributions to biopharmaceuticals and medical devices, continues to enhance its product offerings and global footprint. Highlighted in an August 2024 article by Feliza Mirasol, the company's business expansion strategy focuses on custom single-use
